ABIOMED Inc
Change company Symbol lookup
Select an option...
ABMD ABIOMED Inc
CSCO Cisco Systems Inc
BIP Brookfield Infrastructure Partners LP
OGS ONE Gas Inc
GM General Motors Co
VCYT Veracyte Inc
BLUE bluebird bio Inc
GWPAX American Funds Growth Portfolio Class A
LIXTW Lixte Biotechnology Holdings Equity Warrants Exp 1st Jan 2025 *W EXP 01/01/2025
ZIONP Zions Bancorporation NA
Go

Health Care : Health Care Equipment & Supplies | Mid Cap Growth
Company profile

ABIOMED, Inc. is a provider of medical devices, which provides circulatory support and oxygenation. The Company develops, manufactures and markets its products, which are designed to improve blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists and in the heart surgery suite by cardiac surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. Its operating segment includes the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. Its existing products include Impella 2.5, Impella CP, Impella 5.0 and Impella LD. The Impella 2.5 device is a percutaneous micro heart pump with an integrated motor and sensors. The Impella CP device provides blood flow of approximately one liter more per minute than the Impella 2.5 device.

Closing Price
$235.75
Day's Change
-2.90 (-1.22%)
Bid
--
Ask
--
B/A Size
--
Day's High
242.43
Day's Low
226.46
Volume
(Heavy Day)
Volume:
515,391

10-day average volume:
407,976
515,391

Company Profile

ABIOMED, Inc. is a provider of medical devices, which provides circulatory support and oxygenation. The Company develops, manufactures and markets its products, which are designed to improve blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists and in the heart surgery suite by cardiac surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. Its operating segment includes the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. Its existing products include Impella 2.5, Impella CP, Impella 5.0 and Impella LD. The Impella 2.5 device is a percutaneous micro heart pump with an integrated motor and sensors. The Impella CP device provides blood flow of approximately one liter more per minute than the Impella 2.5 device.

Valuation Ratios

Price/Earnings (TTM)
80.49x
Price/Sales (TTM)
10.53x
Price/Book (MRQ)
7.23x
Price/Cash Flow (TTM)
112.01x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

April 2022
Current Month
1.1M
Previous Month
1.3M
Percent of Float
2.52%
Days to Cover
3.5247 Days

Share Information

ABMD is in a share class of common stock
Float
44.6M
Shares Outstanding
45.5M
Institutions Holding Shares
782
92.79%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in thousands.

Company Officers

  • Michael R. MinogueChmn.
  • Todd A. TrappCFO
  • Marc A. BeganVP
  • Andrew J. GreenfieldVP
  • Dorothy E. Puhy

Address

Insider Trading

During the most recent quarter, 40K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.